A Study With Iron Sucrose in Healthy Volunteers and Chronic Kidney Disease Stage 3-4 Subjects
Status:
Completed
Trial end date:
2019-08-26
Target enrollment:
Participant gender:
Summary
A Phase 1b dose-escalating study evaluating the pharmacodynamic effect of FeS in healthy
volunteers and chronic kidney disease stage 3-4 subjects. Biomarkers will be used as
surrogate measures of protective activity.
Phase:
Phase 1
Details
Lead Sponsor:
Renibus Therapeutics, Inc. Renibus Therapuetics, Inc.